Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$147.1M
19M shares
52-week range
$4.54 – $22.25
17% from low
Sector
SERVICES-BUSINESS SERVICES, NEC
Exchange
NASDAQ
CS
P/S (TTM)
1.4
EV / FCF (TTM)
7.5
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
www.optimizerx.comNo one on the platform currently holds OPRX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 216,856 | $1.4M |
| Execution date | Ratio |
|---|---|
| 2018-05-14 | 1-for-3reverse |
No one on the platform has traded OPRX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 6.8% | — | — | — | ||
| Rev. Growth % | 18.8% | 20.4% | ||||
| Profit Margin % | 4.7% | -11.9% | -11.3% | |||
| Free Cash Flow Margin % | 17.0% | 5.6% | -2.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is -5.3% on the P/E track.
At today's price, your expected annual return is +3.3% on the P/E track.
At today's price, your expected annual return is +13.4% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $97M | -10.6% | $0.91 | $0.87–$0.95 | 8.3× | 3 |
| 2027 | $108M | +11.4% | $1.10 | $0.98–$1.29 | 6.9× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | $0.11 | $0.16 | +44.0% |
| 2026-05-12 | $0.01 | $0.14 | +1300.0% |
| 2026-03-05 | $0.23 | $0.51 | +121.7% |
| 2025-11-06 | $0.03 | $0.20 | +566.7% |
| 2025-08-07 | $0.03 | $0.24 | +700.0% |
| 2025-05-12 | $-0.11 | $0.08 | +172.7% |
| 2025-03-12 | $0.25 | $0.30 | +20.0% |
| 2024-11-13 | $0.06 | $0.12 | +100.0% |
| $495M |
| — |
| RXSTRxSight, Inc. | $5.62 | -7.94% | $233M | — |
| SLPSimulations Plus, Inc. | $18.41 | -0.05% | $372M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$ATHR $CVAT $LXEO $OPRX $PBHC The underlying deal is real — it’s in CVAT’s SEC filing — but the “10.8¢ locked in, 270% return” framing leaves out some key details. The offer price isn’t fixed: it’s calculated as Net Price ÷ shares outstanding, and that gets recalculated at a record date 45 business days after the tender offer even opens, so the final per-share number can still move. The deal also isn’t done — EGS needs at least 90% of shares tendered, plus a separate $7M side-deal for Alchemy Beverages has to close too. And this plays out over months, not days, with the offer staying open 60+ business days and another 30+ after final pricing is set. The gap between the 3-6¢ trading price and the 10¢+ deal price isn’t free money sitting on the table — it’s the market pricing in real risk that this doesn’t close cleanly. Legit news, just not the guaranteed windfall it’s being sold as.
View on StockTwits ↗
$CVAT Cavitation Technologies has execute a buyout for this company at 35 million $. This translate to 10.8c per share, you can finds this on the company SEC filing. The stock right now trades 3.9c, the buyout is for 10.8c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 10.8c Current sp: 3.9c 270% Return on Investment, Tender will start Monday!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! https://www.compuserve.com/pf/story/0022/20260817/9811028.htm $PBHC $LXEO $ATHR $OPRX
View on StockTwits ↗
$OPRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.04 down -150.00% YoY • Reported revenue of $20.5M down -29.77% YoY • OptimizeRx Corp is reiterating its fiscal year 2026 guidance, expecting revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million for the full year.
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-12-optimizerx-co-stock/ $OPRX OptimizeRx Earnings Transcript
View on StockTwits ↗
$OPRX https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=320207725&type=HTML&symbol=OPRX&cdn=b322027f3de0537f02e3d19f5bbee83d&companyName=OptimizeRx+Corporation&formType=SCHEDULE+13G&formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2026-07-22
View on StockTwits ↗
OptimizeRx ( $OPRX ) appoints Sarah Bast as Chief Marketing Officer, adding a veteran point-of-care marketing leader to the team as the company looks to deepen healthcare engagement and growth. #OPRX #OptimizeRx #healthtech #digitalhealth https://prismmarketview.com/companies/optimizerx-corporation/#news
View on StockTwits ↗
$OPRX rolled out its AI-powered Natural Language Audience Builder for life-science DSPs.
View on StockTwits ↗
MissionIRNewsBreaks – $OPRX Secures $35 Million Senior Credit Facility https://ibn.fm/G0Fj3
View on StockTwits ↗$OPRX moves to replace its chief commercial officer and lock in a 12-month advisory agreement with Theresa Greco.
View on StockTwits ↗
$OPRX Share Price: $5.40 Contract Selected: Dec 18, 2026 $5 Calls Buy Zone: $0.89 – $1.10 Target Zone: $1.67 – $2.04 Potential Upside: 76% ROI Time to Expiration: 196 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.